S39 New Developments in the Role and Regulation of the Androgen Receptor

Program: Symposia
Basic Session
Saturday, April 2, 2016: 4:45 PM-6:15 PM
Room 104 (BCEC)
Irina U Agoulnik, PhD, Baylor College of Medicine, Houston, TX

Nothing to Disclose: IUA
4:45 PM
Daniel Gioeli, PhD, Microbiology, Immunology, and Cancer Biology and Cancer Center, Univeristy of Virginia, Charlottesville, VA
Nothing to Disclose: DG
5:15 PM
Nancy L Weigel, PhD, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX
Nothing to Disclose: NLW
5:45 PM
Marianne D Sadar, Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada
Nothing to Disclose: MDS
See more of: Symposia


The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire